Alzamend Neuro, Inc. Operating Income Loss

• Alzamend Neuro, Inc. showed an increase of +54.7% in Operating Income Loss from 2024 to 2025.
• This data is from Alzamend Neuro, Inc.'s annual report (Form 10-K), filed with the SEC on July 22, 2025.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Alzamend Neuro, Inc.'s Operating Income Loss has declined by 1.6%.
• Historical annual values: Fiscal year 2025: -$4.50 million | Fiscal year 2024: -$9.94 million | Fiscal year 2023: -$14.87 million | Fiscal year 2022: -$12.32 million | Fiscal year 2021: -$4.95 million | Fiscal year 2020: -$4.42 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026